Ferric maltol - Shield Therapeutics
Alternative Names: ACCRUFeR; Accrufer; Feraccru; Iron (III) maltol; ST-10; ST10-021Latest Information Update: 12 Sep 2025
At a glance
- Originator University of Cambridge; University of London
- Developer KYE Pharmaceuticals; Norgine; Shield Therapeutics
- Class Antianaemics; Ferric compounds; Pyrones; Small molecules
- Mechanism of Action Iron replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Iron deficiency anaemia
Most Recent Events
- 04 Sep 2025 Ferric maltol receives priority review status for Iron deficiency anaemia (In children, In adolescents) in USA (PO, Liquid)
- 04 Sep 2025 Norgine anticipates approval of sNDA by EMA for Iron deficiency anaemia (In adolescents) in 2026
- 04 Sep 2025 Shield Therapeutics plans to file sNDA for Iron deficiency anaemia (In infants, In children) in USA